waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma (DLBCL).

被引：0
|
作者：
Lavie, David
Ozcan, Muhit
Paszkiewicz-Kozik, Ewa
Barca, Eva Gonzalez
Kim, Tae Min
Puccini, Benedetta
Wang, Siruo
Yusuf, Rushdia
Marinello, Patricia
Kim, Won Seog
机构：
[1] Hadassah Med Ctr, Jerusalem, Israel
[2] Ankara Univ, Sch Med, Ankara, Turkiye
[3] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[4] Univ Barcelona, Inst Catala Oncol Hosp, IDIBELL, Barcelona, Spain
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Unit AOU Careggi, Florence, Italy
[7] Merck & Co Inc, Rahway, NJ USA
[8] Samsung Med Ctr, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7589
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 2 Study of Zilovertamab Vedotin With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab (R-CHP) in Diffuse Large B-Cell Lymphoma: waveLINE-007
    David, Lavie
    Muhit, Ozcan
    Ewa, Paszkiewicz-Kozik
    Eva, Gonzalez Barca
    Min, Kim Tae
    Benedetta, Puccini
    Siruo, Wang
    Rushdia, Yusuf
    Patricia, Marinello
    Seog, Kim Won
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S31 - S32
  • [2] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study
    Tilly, Herve
    Morschhauser, Franck
    Bartlett, Nancy L.
    Sharman, Jeff
    Haioun, Corinne
    Kolibaba, Kathryn S.
    Chen, Andy
    Lamy, Thierry
    Jones, Surai
    Penuel, Elicia
    Lee, Calvin
    Salles, Gilles A.
    BLOOD, 2016, 128 (22)
  • [3] Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation
    Bartlett, Nancy L.
    Chen, Andy I.
    Kolibaba, Kathryn S.
    Lamy, Thierry
    Jones, Surai
    Hirata, Jamie
    Sharman, Jeff P.
    BLOOD, 2015, 126 (23)
  • [4] POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
    Tilly, H.
    Sharman, J.
    Bartlett, N.
    Morschhauser, F.
    Haioun, C.
    Munoz, J.
    Chen, A.
    Lamy, T.
    Wang, L.
    Penuel, E.
    Hirata, J.
    Lee, C.
    Salles, G.
    HAEMATOLOGICA, 2017, 102 : 4 - 4
  • [5] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL): results of the phase III POLARIX study
    Dietrich, S.
    Tilly, H.
    Morschhauser, F.
    Sehn, L. H.
    Friedberg, J.
    Trneny, M.
    Sharman, J. P.
    Herbaux, C.
    Burke, J. M.
    Matasar, M.
    Rai, S.
    Izutsu, K.
    Mehta-Shah, N.
    Oberic, L.
    Chauchet, A.
    Jurczak, W.
    Song, Y.
    Greil, R.
    Mykhalska, L.
    Burgues, J. M. B.
    Cheung, M. C.
    Pinto, A.
    Shin, H-J
    Hapgood, G.
    Munhoz, E.
    Abrisqueta, P.
    Gau, J-P
    Hirata, J.
    Jiang, Y.
    Yan, M.
    Lee, C.
    Flowers, C.
    Salles, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 193 - 194
  • [6] Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
    Flowers, Christopher
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua-Burgues, Juan Miguel
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S358 - S359
  • [7] Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-r-chp) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (r-chop) therapy in patients with previously untreated diffuse large b-cell lymphoma (dlbcl): results from the phase iii polarix study
    Dietrich, Sascha
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yu Qin
    Greil, Richard
    Mykhalska, Larysa
    Bergua Burgues, Juan Miguel
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Salles, Gilles
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 165 - 165
  • [8] Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
    Vitolo, Umberto
    Trneny, Marek
    Belada, David
    Burke, John M.
    Carella, Angelo Michele
    Chua, Neil
    Abrisqueta, Pau
    Demeter, Judit
    Flinn, Ian
    Hong, Xiaonan
    Kim, Won Seog
    Pinto, Antonio
    Shi, Yuan-Kai
    Tatsumi, Yoichi
    Oestergaard, Mikkel Z.
    Wenger, Michael
    Fingerle-Rowson, Gunter
    Catalani, Olivier
    Nielsen, Tina
    Martelli, Maurizio
    Sehn, Laurie H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) : 3529 - +
  • [9] The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
    Tilly, Herve
    Morschhauser, Franck
    Sehn, Laurie H.
    Friedberg, Jonathan W.
    Trneny, Marek
    Sharman, Jeff P.
    Herbaux, Charles
    Burke, John M.
    Matasar, Matthew
    Rai, Shinya
    Izutsu, Koji
    Mehta-Shah, Neha
    Oberic, Lucie
    Chauchet, Adrien
    Jurczak, Wojciech
    Song, Yuqin
    Greil, Richard
    Mykhalska, Larysa
    Bergua Burgues, Juan Miguel
    Cheung, Matthew C.
    Pinto, Antonio
    Shin, Ho-Jin
    Hapgood, Greg
    Munhoz, Eduardo
    Abrisqueta Costa, Pau
    Gau, Jyh-Pyng
    Hirata, Jamie
    Jiang, Yanwen
    Yan, Mark
    Lee, Calvin
    Flowers, Christopher R.
    Salles, Gilles
    BLOOD, 2021, 138
  • [10] The POLARIX Study: Polatuzumab Vedotin With Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone vs Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
12345